Global Oncology Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
According to our (Global Info Research) latest study, the global Oncology Drugs market size was valued at US$ 225860 million in 2023 and is forecast to a readjusted size of USD 438600 million by 2030 with a CAGR of 10.1% during review period.
The industry"s leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.
This report is a detailed and comprehensive analysis for global Oncology Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Oncology Drugs market size and forecasts, in consumption value ($ Million), 2019-2030
Global Oncology Drugs market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Oncology Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Oncology Drugs market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oncology Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oncology Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Oncology Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Oncology Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Market segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
Market segment by players, this report covers
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncology Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncology Drugs, with revenue, gross margin, and global market share of Oncology Drugs from 2019 to 2024.
Chapter 3, the Oncology Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Oncology Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Drugs.
Chapter 13, to describe Oncology Drugs research findings and conclusion.